Nasal Drop Therapy for ALS
Part of Brain & nervous system, Hormones & metabolism clinical trials.
This trial tests a nasal drop made from tiny cell particles (extracellular vesicles) for ALS. The goal is to see if it's safe and if it can slow down the disease. It may be an option if your ALS is in the early to moderate stage.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 to 80 years old.
- You should have had ALS symptoms for 6 months to 2 years.
- Your ALS must be diagnosed as "Definite," "Probable," or "Possible" ALS.
- You need a breathing test score (FVC) of 70% or higher.
- You cannot have serious nose problems, low blood counts, or certain infections.
- If you take riluzole or edaravone, the dose must have been the same for at least 30 days.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new nasal drop treatment made from stem cells for people with Alzheimer's, Parkinson's, multiple system atrophy, Lewy body dementia, frontotemporal dementia, or ALS. The drops may help slow disease progression by delivering tiny healing particles directly to the brain through the nose.
This trial tests whether injecting neural stem cells into the spine can slow down ALS. It is for people with rapidly progressing ALS who have good lung function and a caregiver to help with visits.
This study tests a new stem cell treatment called NurOwn for people with early ALS (within 2 years of symptoms) who still have good breathing and daily function. The goal is to see if it can slow the disease.
This trial studies an experimental drug called LTX-002 for people with ALS. It aims to see if the drug is safe and can slow down the disease.
This trial tests whether adding two supplements (EH-301 and N-acetylcysteine) to the standard ALS medicine Riluzole can help slow the disease. It is for people diagnosed with ALS within the last 18 months who still have good breathing and daily function.
This study tests a therapy made from human amniotic cells to help reduce brain inflammation and damage. It may be an option for people with ALS or multiple sclerosis who meet the age and health requirements, as well as healthy volunteers to serve as a comparison group.
Hear when a new Amyotrophic Lateral Sclerosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.